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"Double hit" lymphoma or secondary
MYC translocation lymphoma?
Abstract
Chromosomal translocations that juxtapose different genes required for
proliferation and differentiation are frequently associated with hematologic
neoplasms. A term "double hit" lymphoma refers to a group of mature
B-cell malignancies that harbor MYC rearrangement accompanied with
another translocation commonly found in lymphomas (i.e. IGH/BCL2). A
complex karyotype with multiple abnormalities and very aggressive course
of disease are additional characteristics of this group. The response to cur-
rently available treatment regimens is unsatisfying, thus reported overall
survival of these patients is usually very short. Today, the precise mechanisms
of "double hit" lymphoma development are still unclear, although several
possible pathways have been proposed in the literature. Similar oncogenic
chain of events was also observed in another common hematological malig-
nant neoplasm – multiple myeloma. MYC translocation as a secondary
pathogenic phenomenon has been demonstrated in multiple myeloma, as
well as complex cytogenetics and very aggressive course of the disease. There-
fore, a secondary translocation involving MYC gene might be a potential
marker of aggressive neoplasms emerging from different cells of origin, and
united under the umbrella of "MYC-plus" malignancies. That concept
might, in the future, result in a novel therapy, targeting this distinct, but not
unique cytogenetic aberration.
WHO CLASSIFICATION OF LYMPHOMAS
Acommonly used term 'lymphoma' portrays not a single disease, butmore than 40 biologically, morphologically and clinically different
entities within the category of malignant neoplasms of lymphoid line-
age. Classifications are an essential part of modern medicine, offering a
consensus on terminology and disease definitions to be used interdis-
ciplinary both in research and clinical practice. Evolution of lymphoma
classifications includes numerous attempts from descriptive schemes,
relying on morphology (in the Rappaport classification) to strictly
clinically oriented stratifications proposed by hematologists (as in the
Working Formulation), usually without significant international ac-
ceptance (1). The 3rd edition of The World Health Organization (WHO)
Classification of Tumours of the Haematopoietic and Lymphoid Tis-
sues that was published in 2001 was regarded as a milestone, because it
was the first classification consistently to be used worldwide (2).
The WHO classification divides lymphomas primarily into Hodgkin
lymphomas and non-Hodgkin lymphomas. Non-Hodgkin lympho-
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well as B or T cell (NK cell) lineage (precursor lymphoid
neoplasms and mature B-cell and T/NK-cell neoplasms).
The principles of classification of lymphoid neoplasms
include a multiparameter approach to disease definition:
they are based on morphology, immunophenotype and
genetics, as well as clinical features of disease entities.
Furthermore, lymphomas are usually classified accord-
ing to their presumed normal counterpart, although some
of them, especially the aggressive forms, lack obvious
normal counterparts. The currently used 4th edition of
the WHO classification brought important changes based
mainly on new genetic information; redefined consensus
guidelines for some diseases, introduced new entities,
subtypes and variants of lymphomas, provisional catego-
ries, and importantly borderline (grey zone) categories.
In this review we will focus on a particular subgroup of
mature lymphoid neoplasms with B-cell immunophe-
notype and aggressive clinical behavior, "double hit" lym-
phomas (3).
Aggressive B-cell lymphomas
In previous classifications most aggressive B-cell neo-
plasms were conveniently designated as diffuse large
B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) or
Burkitt-like lymphoma (atypical Burkitt lymphoma). In
the current WHO classification the complexity of this
subgroup is reflected in a long list of entities and disease
variants (Table 1), and the diagnosis of Burkitt-like lym-
phoma is abolished. Interestingly, some of them are de-
fined by specific genetic abnormalities (e.g. ALK-po-
sitive large B-cell lymphoma), and others by viral agents
contributing to B-cell transformation (e.g. primary effu-
sion lymphoma, large B-cell lymphoma arising in
HHV-8-associated multicentric Castleman disease) or
even age (EBV-positive DLBCL of the elderly). It also
introduced two new, controversial categories of grey zone
lymphomas, both defined by overlapping morphological,
immunophenotypic and clinical features, with majority
of "double hit" lymphomas currently classified as B-cell
lymphoma, unclassifiable, with features intermediate
between DLBCL and Burkitt lymphoma. Some of these
aggressive malignancies of B-cell origin share striking
morphologic similarities (Figure 1), as well as genetic
aberrations involving MYC gene, and will be further
discussed in more details.
Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a B-cell lymphoma
composed of monomorphous small to medium-sized
lymphoid cells with irregular nuclei and a translocation
involving the cyclin D1 gene (3). Postulated normal
counterpart of the tumor cell is a mature B-cell of inner
mantle zone (usually of naïve pre-GC type). It usually
affects middle-aged to older patients with a median age
of approximately 60 (4). Microscopically, several archi-
tectural patterns of MCL are observed, such as diffuse,
nodular, mantle zone, and rarely marginal zone pattern.
Morphologic variants include the small cell variant with
a more indolent course and blastoid/pleomorphic vari-
ants, usually with high proliferation fraction, dispersed
chromatin pattern and associated with an aggressive cli-
nical behavior (5). Immunohistochemically tumor cells
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TABLE 1
Aggressive B-cell lymphomas in the WHO Classification (2008).
# Variants of mantle cell lymphoma
Diffuse large B-cell lymphoma, not otherwise specified
Diffuse large B-cell lymphoma subtypes
• T-cell/histiocyte-rich large B-cell lymphoma
• Primary DLBCL of the CNS
• Primary cutaneous DLBCL, leg type
• EBV-positive DLBCL of the elderly
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
DLBCL associated with chronic inflammation




Large B-cell lymphoma arising in HHV-8-associated multicentric Castleman disease
Burkitt lymphoma
*B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma
*B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma
# Aggressive variants include blastoid and pleomorphic mantle cell lymphoma
§ In most patients the disease is aggressive (grade 3), although patients with grade 1 and 2 lesions follow a more indolent clinical course
* Borderline (grey zone categories)
typically express CD20, BCL2 and CD5, as well as cyclin
D1, although rare cases can be CD5- and cyclin D1-ne-
gative. The t(11;14)(q13;q32) is present in almost all cases
and is considered the primary genetic event, although
some MCL with no evidence of such translocation have
been reported (6). Some of them harbor a t(2;12)(p12;p13)
translocation involving cyclin D2 and kappa light chain
gene (IgK) (7).
Diffuse large B-cell lymphoma
For a long time DLBCL was a "wastebasket" diag-
nosis comprising myriad of morphologically similar, but
pathogenetically and clinically different disease entities.
Today it is divided in many variants, subgroups and
subtypes, largest of which is DLBCL – not otherwise
specified (NOS). It is a tumor defined by diffuse prolife-
ration of large B-cells. Even DLBCL-NOS is morpholo-
gically and imunophenotypically a heterogenous category
of lymphomas, divided in several variants (Table 2) (3).
Postulated normal counterparts are mature B-cells of
either germinal center or post-germinal center stage of
differentiation.
Most patients present with a rapidly enlarging mass
and the disease affects nodal and extranodal sites. It usu-
ally occurs in adults and the frequency increases with age.
The tumor cells are positive for B-cell markers (CD20,
CD19, CD79A), and some cases demonstrate aberrant
expression of CD5 or CD43 (8, 9). Expression of CD10,
BCL6, and MUM1/IRF4 is variable, and is the basis of
immunohistochemical stratification into GCB and non-
-GCB subgroup (prognostic value of such subdivision is
a matter of ongoing debate because of poor reproduci-
bility of immunohistochemical staining analysis) (10,
11). On the other hand, gene expression profiling (GEP)
allows a reproducible identification of two prognostically
different subgroups (GCB and ABC), with apparently
different cells of origin (12-14). Approximately 10% of
DLBCL harbor a MYC translocation, linked with an
unfavorable outcome (15, 16). DLBCL is an aggressive
lymphoma, usually resulting in death within 1 or 2 years
without treatment (17).
Burkitt lymphoma
This is an aggressive lymphoma that often presents in
extranodal sites or as an acute leukemia, characterized by
the translocation involving MYC gene. There are three
main clinical variants of the disease: endemic BL (typi-
cally affecting children in equatorial Africa and com-
monly associated with EBV), sporadic BL (mainly in
children and adolescents throughout the world), and
immunodeficiency-associated BL (primarily in the sett-
ing of HIV infection), showing differences in clinical
features, biology, and even morphology (3). The tumor is
composed of cohesive proliferation of monotonous, me-
dium-sized cells with finely clumped and dispersed
chromatin and deeply basophilic cytoplasm. Postulated
cell of origin is a GC or post GC mature B-cell. This
lymphoma has an extremely high proliferation index, as
well as high fraction of apoptotic cells, with a typical
"starry sky" pattern. Tumor cells typically express pan-B
markers (CD19, CD20, CD22), almost invariably show
diffuse positivity for CD10, BCL6 and are uniformly
negative for TdT (marker of immature lymphoid cells
expressed in precursor lymphoid neoplasms). BCL2 is
usually negative or rarely weakly positive in a minority of
tumor cells. MYC translocation is present in virtually all
BL, although it is not specific, and usually involves the
IGH gene (3). MYC translocation is considered a pri-
mary event in BL, and typically no other (or very few)
cytogenetic abnormalities are present, depicted by the
term "simple karyotype" (18). This is a very aggressive,
but potentially curable disease in cases of endemic and
sporadic BL.
B-cell lymphoma, unclassifiable, with features
intermediate between DLBCL and Burkitt
lymphoma – grey zone lymphoma
This controversial category comprises rare B-cell lym-
phomas that demonstrate overlapping morphological and
genetic features of both DLBCL and BL and particularly
aggressive clinical course. They usually affect adults and
older individuals. Before the 2008 classification many of
them were diagnosed as Burkitt-like lymphoma or aty-
pical Burkitt lymphoma. It is a heterogenous category,
incorporating several biologically and pathogenetically
different entities, but today the methods to precisely diag-
nose and define those are still lacking. Nevertheless, the
importance of this grey zone lies in the fact that these
lymphomas are resistant to currently available treatment
regimens, hence these patients should not be included
into the well-defined categories of DLBCL or BL. Mor-
phologically these tumors consist of diffuse proliferation
of medium and large-sized atypical lymphoid cells, with
variable number of cells with typical centroblastic mor-
phology. The variability of cell size and shape is usually
greater than in BL, and some cases are morphologically
indistinguishable from DLBCL. Tumor cells express B-cell
markers, and often share most immunophenotypical fea-
tures with BL (CD20+, CD10+, BCL6+, BCL2-), al-
though many of them show strong and diffuse expression
of BCL2, which is incompatible with the diagnosis of
BL. The proliferation index is usually very high. (19).
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These tumors often harbor MYC translocations as a se-
condary oncogenic event, but unlike in BL, the translo-
cation partner is frequently a light-chain or a non-IG
gene (20). A complex karyotype with multiple abnor-
malities is another feature differentiating these lympho-
mas from BL (21). A subgroup of grey zone lymphomas
that has recently received an overwhelming attention in
the field of hematopathology are so called "double-hit"
lymphomas. They are characterized by dual transloca-
tions, involving MYC and BCL2, or other genes such as
BCL6, CCND1, BCL3. They can occur de novo, or as a
result of follicular or mantle cell lymphoma transfor-
mation (22, 23). The diagnosis of "double-hit" lympho-
ma is challenging because no specific morphological or
immunophenotypic criteria have been defined. These
patients often have significant extranodal involvement
including the bone marrow and CNS, and a very poor
prognosis with a median survival of only 0.2-1.5 years
(20, 21).
Plasmablastic lymphoma
This is a lymphoma composed of large cells that mor-
phologically resemble immunoblasts, but demonstrate a
plasma cell immunophenotype. The postulated cell of
origin is a plasmablast (immature lymphoid cell of B-line-
age switched to the plasma cell gene expression pro-
gram). It usually occurs in the setting of HIV infection,
mainly in adults. The typical sites of involvement are oral
cavity, and other extranodal mucosal sites (sinonasal ca-
vity, orbit, gastrointestinal tract) (24). Tumor cells express
plasma cell markers CD138, CD38, MUM1/IRF4, EMA,
and are usually negative for pan-B markers (CD20, PAX5).
In situ hybridization for detection of EBV is positive in
the majority of plasmablastic lymphomas. This is an
aggressive disease with a median survival of 6 to 7 months
(25, 26).
Plasma cell myeloma (multiple myeloma)
This is a plasma cell neoplasm with a wide spectrum
of clinical presentations including indolent and highly
aggressive forms. It is characterized by a clonal prolife-
ration of mature plasma cells associated with an M-pro-
tein in serum and urine, and generalized bone marrow
involvement. Postulated normal counterpart is a post-GC
plasma cell demonstrating IG class switch and somatic
hypermutation. Tumor cells typically express CD138,
CD79A, and CD38, but unlike normal plasma cells they
are usually CD19 negative and often show aberrant ex-
pression of CD56. Cyclin D1 can also be positive in a
subset of myelomas (27). Numerous genetic abnormali-
ties include trisomies, hyperdiploidy, deletions and trans-
locations. Complex cytogenetic aberrations are common
(28). The most frequent translocations affect IGH and
partner genes such as CCND1, C-MAF, FGFR3/MMSET,
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Figure 1. A) Burkitt lymphoma, B) B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma. C)
diffuse large B-cell lymphoma-NOS, D) mantle cell lymphoma, E) plasmablastic lymphoma, F) multiple myeloma. A-F hematoxylin-eosin
staining; original magnification x400 (A-E) and x630 (F).
CCND3, and MAFB (29). One of the most common
structural abnormalities that occurs early in the patho-
genesis is monosomy or partial deletion of chromosome
13 (13q14), and it is associated with disease progression
(30). MYC rearrangement occurs as a secondary event
during the pathogenesis (3). Plasma cell myeloma is
incurable, with a wide range of survival (from 6 months
to 10 years and more) (31).
Genes involved in the "double hit"
concept
MYC
MYC or c-MYC (myelocytomatosis viral oncogene
homolog) gene located at 8q24.21 was recognized in
1982 as a significant part of the translocation present in
Burkitt lymphoma (32, 33). In the following years it was
confirmed that c-MYC is translocated not only in mouse
plasmacytomas, but also in human Burkitt lymphoma
cells, with different translocation (most frequently with
IG partners) constituting a possible reason for observed
high level of its transcripts. It was also proposed that
aberrant transcription control is one of the characteristics
of B-cell neoplastic transformation (34-39). Moreover, it
was vaguely suggested that c-MYC translocation is, at
least in plasmacytoma, "not the only step in induction",
but possibly a secondary translocation (40). The first
studies of human protein encoded by c-MYC suggested
that this protein has affinity for both single and double
stranded DNA and that it is localized in the nucleus (41,
42). Furthermore, it was shown that c-MYC protein has a
role in DNA synthesis and that it forms a dimer with
MAX protein, resulting in a complex that binds to DNA
in a sequence-specific manner, thus regulating activation
of various genes and influencing proliferation and diffe-
rentiation (43-47). Numerous studies were performed
and revealed that c-MYC gene regulation control works
in dual manner: it induces genes involved in activation of
translational initiation, cell cycle regulators, DNA repair
genes, genes involved in metabolism and stress response,
but also represses genes involved in cell growth arrest and
cell adhesion (48, 49). Beside direct control of gene expres-
sion, c-MYC can regulate expression indirectly, through
repression of various miRNA (50, 51).
In neoplastic cells genomic alterations of c-MYC most
frequently involve translocations and amplifications, MYC
rearrangement being the main aberration associated with
the development of Burkitt lymphoma, diffuse large B-cell
lymphoma and double-hit lymphoma. In all those entities,
c-MYC rearrangements mark aggressive tumor behavior
(3). In B-cell lymphomas, activation-induced cytidine
deaminase (AID) is necessary for chromosomal breaks
leading to IGH/MYC translocation (t(8;14)(q24;q32)),
suggesting that this translocation occurs during the stages
of B-cell development in which antibody class switch re-
combination or somatic hypermutation take place (52-54).
t(8;14)(q24;q32) is also found in plasmacytoma/multiple
myeloma where it is regarded as a secondary transloca-
tion. IGH switch recombination and somatic hypermu-
tation mechanism in normal plasma cells and neoplastic
plasma cells are turned off, therefore the mechanism of
this translocation in plasma cells differs from the one in
B-cell lymphomas. Interestingly, the same translocation
is again associated with the unfavorable outcome of the
disease (55-57). Moreover, IG/MYC translocations are
observed as a frequent event in plasmablastic lymphoma,
an aggressive lymphoma in which MYC activation is
believed to hold very important role in disease develop-
ment (58).
BCL2
BCL2 (B-cell CLL/lymphoma 2), located at 18q21, is
a gene that encodes the protein located in the inner
membrane of mitochondria and serves as an antiapop-
totic guardian (59-62). There are two isoforms of BCL2
protein that differ slightly in hydrophobic binding
groove, and therefore have different binding properties
responsible for interaction with Bad and Bak proteins,
suggesting a role in at least two different antiapoptotic
pathways (63). BCL2 gene was first described in 1984 in
follicular lymphoma cells where it forms translocation
with the immunoglobulin heavy chain locus on chromo-
some 14 (64). The same translocation was later found in
diffuse large B-cell lymphoma, primary cutaneous mar-
ginal zone B-cell lymphoma, histiocytic/dendritic cell
sarcomas arising from follicular lymphoma, chronic lym-
phocytic leukemia, monoclonal B-cell lymphocytosis,
small lymphocytic lymphoma and splenic marginal zone
lymphoma. In all these entities IGH/BCL2 is responsible
for constitutive expression of BCL2 protein (65-70). Apart
from being an important factor contributing to lympho-
magenesis, IGH/BCL2 was observed in healthy indivi-
duals. A clone of normal lymphocytes harboring this
translocation can be persistent and more frequently pre-
sent in elderly individuals (71, 72). The presence of the
translocation in healthy individuals, as well as its rela-
tively early occurrence in the B-cell development (during
V(D)J recombination) suggest it is indeed important, but
also an insufficient step in lymphoma development (73).
World Health Organization Classification takes into ac-
count its importance not only in follicular lymphomage-
nesis, but also as a variable needed for assessment of
"double-hit" lymphomas (3).
BCL6
BCL6 (B-cell CLL/lymphoma 6) is located at 3q27.
Baron B W et al. proposed its name in 1993 and consi-
dered it as a gene that "plays a role in the pathogenesis of
certain B-cell lymphomas" (74). It codes a transcription
factor that can, due to its N-terminal POZ domain,
self-interact or interact with many different proteins and
act as a sequence-specific repressor of transcription (75-78).
Its expression is especially important for formation and
function of germinative centers where it protects B- cells
from apoptosis induced by double strand DNA breaks
(DNA breaks required for immunoglobulin class switch
recombination and somatic hypermutation) (79-82).
BCL6 is involved in cell cycle regulation, DNA repair
mechanisms, apoptosis, proliferation and differentiation
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(81, 83-86). It directly controls many genes, in specific
BCL2 and p53 (80, 86, 87). Genetic aberrations of BCL6
are mainly found in diffuse large B-cell lymphoma and
follicular lymphoma, in a form of translocation or point
mutations (3, 88-90). BCL6 expression by tumor cells in
DLBCL is one of key variables in algorithms for distin-
guishing groups of patients with better or worse survival
and therapy response (10, 11). BCL6 translocation to any
of its numerous partners is considered one of the few pos-
sible events that can mark double-hit lymphoma (3, 91).
CCND1
CCND1 (cyclin D1) or BCL1, gene located at 11q13,
codes a protein necessary for transition from G1 to S
phase of the cell cycle. It forms a complex with kinase
CDK4 and through its activity, mostly by influencing
pRb function, regulates the beginning of the cycle (92). It
is not expressed in normal lymphoid or myeloid lineages,
but its overexpression has been described in mantle cell
lymphoma (93, 94). Genetic aberration that is behind its
overexpression seen in B-cell neoplasms is the trans-
location t(11;14)(q13;q32) – IGH/CCND1 (94-98). This
translocation is characteristic of mantle cell lymphoma
but, in high percentage, it can also be found in multiple
myeloma, where it is a consequence of different break-
points (3, 99). In mantle cell lymphoma, IGH/CCND1 is
a result of CpG double-strand break mechanism that
suggests this translocation happens during the pro B-cell
developmental stage (100). Translocation itself is not
necessarily a pathogenetic event – it was also found in
healthy individuals (101). In rare cases of B-cell "double
hit" lymphomas this translocation is believed to be the
first step of the pathogenesis (3, 102).
BCL3
BCL3 (B-cell leukemia/lymphoma 3) gene is located at
19q13.32. Translocation (14;19)(q32;q13.1), which brings
together BCL3 and switch region of the IGH gene, was
first found in chronic lymphocytic leukemia and acute
biphenotypic leukemia (103, 104). Breakpoints respon-
sible for this translocation are believed to be the result of
aberrant class switch recombination (105). On a mouse
model, it was shown that BCL3 expression varies through
different stages of B-cell development and that its tran-
scripts are present in a higher amount during mature
B-cell stages (106). BCL3 codes a protein that belongs to
a I kappa B group. It specifically binds to a NF-kappa B
p50 subunit, thus interfering with inhibitory role that
those homodimers have on a transcription of various
genes (107, 108). BCL3 activity is mediated by phospho-
rylation that allows its association with different partners
and subsequently controls expression of different targets
genes. (109) Furthermore, BCL3 inhibits p53-induced
apoptosis (110).
Possible mechanisms of "double hit"
lymphoma development
"Double hit" lymphomas are defined as aggressive
B-cell lymphoma variants that are marked by MYC rear-
rangement and at least one other recurrent translocation
(3). (Figure 2) In mature B-cell lymphomas the other
"hit" usually involves BCL2, BCL6 and/or CCND1 genes.
Along with a second hit, so far, all reported cases show
complex cytogenetics with additional genetic alterations
(23). In all cases of mature B-cell "double hit" lymphomas
MYC translocation is considered to be a secondary event
based on a timing of breakpoints responsible for certain
translocations during normal B-cell development (23).
In BCL2+ /MYC+ lymphomas, there are two possible
scenarios. The first possibility is that BCL2 translocation
is already present in a B-cell clone of a healthy indi-
vidual. MYC translocation happens as a part of complex
pathogenic karyotype and forms additional change on
the ground of the already present aberration. In the other
possible scenario, BCL2 translocation is indeed one part
of the oncogenic pathway (as in follicular lymphoma),
followed by further aberrations involving the MYC gene
(23). In both cases, the result is a "double hit" that might
cause antiapoptotic behavior of cells, with changes in
gene expression control through suppression of growth
arrest, and induction of constitutive proliferation and
differentiation signals. The promotion of such aberrant
differentiation could be the key point that affects the
severity of the disease. An idea that such pathways exist
has been implied incoherently during last decade. In
2005 Martin-Subero et al. described two cases, showing
that IGH/BCL2 accompanied by MYC aberration causes
aggressive behavior of germinal center B-cell lymphomas
(111). In the same year, another group reported a case of
follicular lymphoma with IGH/BCL2 and its subsequent
transformation to atypical Burkitt lymphoma (according
to the 2008 WHO classification, grey zone lymphoma),
due to additional IGH/MYC translocation (112).
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Figure 2. A) MYC gene rearrangement; B) IGH/c-MYC transloca-
tion; C) BCL2 gene rearrangement; D) BCL6 gene rearrangement.
A, C, D – single red and green signals represent split loci, B-fusion
(yellow) signals represent reciprocal translocation.
CCND1+ /MYC+ lymphomas could share similar on-
cogenic pathways: IGH/CCND1 is either a non-onco-
genic aberration present in a small population of B-cells
of healthy individuals, or the first step in the patho-
genesis, similar as in the pathogenesis of mantle cell
lymphoma. MYC rearrangement brings an additional
change that adds aggressive potential to the neoplastic
cell (23). IGH/CCND1 results in constitutively induced
CCND1 that forces B-cell to enter mitosis possibly with-
out enough time required for damage checkpoints, thus
allowing multiple aberrations to persist and cause more
changes in the transcription control. MYC rearrange-
ment, again, could additionally promote proliferation
and/or activate transcription of other oncogenes causing
aggressive behavior of the neoplasm.
Third group are BCL6+/MYC+ lymphomas that are
mostly "triple hit" BCL2+/BCL6+/MYC+ lymphomas (23).
This entity displays synergistic action of BCL2 and MYC
with an additional event, which might result in protec-
tion of B-cells from apoptosis, induced by double strand
DNA breaks. Rare BCL6+/MYC+ lymphomas could ma-
nifest a constant antiapoptotic signal from constitutively
active BCL6 accompanied by induced proliferation due
to constant activation of various oncogenes by MYC.
BCL3+/MYC+ lymphomas are extremely rare "double
hit" entities. The underlying oncogenic pathway is most
probably based on a constant antiapoptotic BCL3 acti-
vity, followed by transcriptional activation of genes re-
quired for proliferation and differentiation induced by
MYC rearrangement.
Clinical presentation, current
treatments and future need for therapy
In 2011, Aukema SM et al. analyzed the Mitelman
database and cases reported in published studies, in order
to review clinical data and treatment protocols concern-
ing "double hit" lymphomas. They reported that "double
hit" lymphoma patients were mostly in their 5th and 6th
decades, have elevated LDH levels, extranodal involve-
ment, high International Prognostic Index (IPI) stage
and that the diagnosis was established usually in the
advanced stage of the disease. In different studies, they
documented various treatment protocols: high-dose che-
motherapy, stem cell transplantation, specific antibody
treatment (rituximab), bone marrow transplantation, ra-
diotherapy, combination of those, and even in some cases
steroids as a form of palliative therapy. Overall survival
was never longer than a year and a half (23).
Hence, it seems that the category "double hit" lym-
phoma is just a temporary title for B-cell lymphomas
with highly aggressive biologic potential, evident not
only in gene rearrangements behind its development, but
also in different clinical aspects that accompany such
disease progression. Subsequently, patients that belong
to this group require a new treatment regimen, possibly a
therapy based on repression of oncogenic mechanisms
arising from a "double hit" concept, or a protocol that
would eliminate the effect of complex cytogenetic aberra-
tions in the neoplastic cells.
DISCUSSION
"Double hit" lymphomas are, by definition, a highly
aggressive B-cell lymphomas with MYC rearrangement
plus additional recurrent translocation and a very com-
plex karyotype (3). In the recent literature, it was clearly
stated that this is a temporary category that should be
used until enough data for better classification were col-
lected (23).
All disease classifications were written out of a need
for better understanding of disease development in order
to stratify and treat patients with adequate therapies. In
case of hematological neoplasms, detailed attempts of
lymphoma classification go back to Rappaport classifica-
tion (1). Classification was at first based on tumor cell
morphology and its similarity to normal cell counter-
parts. Later, gradually, different classifications take into
account clinical behavior, cell surface markers, different
antigen expression and genetic aberrations (2, 3, 113,
114). With time, due to gathered knowledge, it was pos-
sible to divide hematological diseases in many different
groups, describe them very precisely, recognize pathways
responsible for their development, and therefore to treat
them almost specifically aiming at certain tumor charac-
teristics (115-118). Today, the abundant available data
about tumorigenesis allow us to stratify patients preci-
sely, although it is still impossible to decipher crucial and
therapeutically applicable pathogenetic events. "Double
hit" lymphomas represent a group that encounters this
problem. In the latest WHO classification, "MYC- plus
B-cell lymphomas" belong to the grey zone category
called "B-cell lymphoma, unclassifiable, with features
intermediate between DLBCL and Burkitt lymphoma"
(3). As explained so far, the clinical presentation of those
lymphomas most probably stems from the secondary
MYC rearrangement and/or complex cytogenetics ob-
served in almost all cases. Interestingly, the addition of
MYC aberration to an already active pathogenetic path-
way and its clinical manifestation in a form of aggressi-
veness is not a new concept, neither is it restricted to
mature B-cell lymphomas. Adams MJ et al. in 1983 sug-
gested that "plasmacytoma oncogenesis appears to invol-
ve both translocation of c-MYC and activation of another
oncogene". Although their research was based on plas-
macytoma cells lines, the postulated oncogenic mechanism
involved MYC rearrangement plus additional aberration
(40). MYC rearrangement as a secondary event was also
observed in multiple myeloma and plasma cell leukemia.
Mechanism responsible for MYC rearrangement in those
neoplasms is still unclear, but it is most certainly different
from those in mature B-cell lymphomas (55-58). Shared
characteristics between plasma cell neoplasms and B-cell
"double hit" lymphoma involve secondary MYC aberra-
tion (the result of different breakpoint mechanisms),
complex karyotype, aggressive biological behavior and a
decrease, or even loss of CD20 expression (3, 119). More-
over, in 2010 Ouansafi I et al. described a case of follicular
lymphoma with transformation to plasmablastic lym-
phoma, possibly due to MYC rearrangement (120).
Period biol, Vol 114, No 4, 2012. 533
"Double hit" lymphomas Petra Kora} et al.
In conclusion, all secondary MYC hematological neo-
plasms display fascinating similarities. Their morpho-
logy, phenotype, basic genetic aberrations and postulated
cells of origin differ, but the clinical aspect of those ag-
gressive neoplasms and the main underlying pathogenic
mechanisms might put them in the same category. The
key event – a secondary MYC translocation, could inte-
grate neoplasms emerging from different cells of origin
into one group, with potential novel therapy targeting a
distinct, but not unique aberration (121).
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